Prostate Imaging Using MRI +/- Contrast Enhancement (PRIME)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04571840|
Recruitment Status : Recruiting
First Posted : October 1, 2020
Last Update Posted : May 18, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
This prospective clinical trial (PRostate Imaging using Mri +/- contrast Enhancement (PRIME)) aims to assess whether biparametric MRI (bpMRI) is non-inferior to multiparametric mpMRI (mpMRI) in the detection of clinically significant prostate cancer.
This means that we are comparing MRI scans that requires injection of IV contrast (the current standard practice) versus MRI scans that can be performed without IV contrast in the detection of prostate cancer.
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Diagnostic Test: Multiparametric MRI +/- prostate biopsy Diagnostic Test: Biparametric MRI +/- prostate biopsy||Not Applicable|
The PRECISION study (NCT02380027) has established that multiparametric MRI +/- targeted biopsy of suspicious areas identified on MRI is superior to standard 12 core TRUS biopsy in the detection of clinically significant prostate cancer (Gleason > 3+ 4) (38% vs 26%), in reducing the detection of clinically insignificant prostate cancer (Gleason 3 + 3) (9% vs 22%) and in maximising the proportion of cores positive for prostate cancer (44% vs 19%).
Multiparametric MRI (mpMRI) typically uses T2-weighted (T2W), diffusion-weighted (DWI) and dynamic contrast enhanced (DCE) sequences. As a mpMRI is a precious resource, due to capacity and resource limitations, one of the major challenges across institutions is delivering a health service with pre-biopsy MRI before a biopsy in all men with suspected prostate cancer.
However, biparametric MRI (bpMRI), that is, a combination of T2W and DWI, which does not use the DCE sequences, has demonstrated similar detection rates of prostate cancer as mpMRI in some studies and there is a debate about the necessity of the DCE sequence.
The potential advantages of avoiding the DCE sequence include avoiding the cost associated with it, shorter scan time, avoiding the need for medical practitioner attendance, and avoiding putative basal ganglia accumulation and the possibility of adverse neurological effect. Thus, a bpMRI approach may be more feasible and have health-economic benefits over a mpMRI approach and may thus increase the accessibility of this resource to men who need it.
PRIME is a multi-centre study. Men referred with clinical suspicion of prostate cancer based on raised prostate specific antigen (PSA) or abnormal digital rectal examination (DRE) who have had no prior biopsy undergo mpMRI. The DCE sequence is blinded from the radiologist who reports the bpMRI first. After reporting the bpMRI, the DCE sequence is made available to the radiologist who reports the mpMRI. The MRIs and lesions are scored on 1-5 scales of suspicion for the likelihood that clinically significant cancer is present:
- - Very low (clinically significant cancer is highly unlikely to be present)
- - Low (clinically significant cancer is unlikely to be present)
- - Intermediate (the presence of clinically significant cancer is equivocal)
- - High (clinically significant cancer is likely to be present)
- - Very high (clinically significant cancer is highly likely to be present)
Men with non-suspicious MRI on bpMRI and mpMRI and low clinical risk of prostate cancer will be counselled by their clinical teams as per routine clinical care. In routine clinical practice these men typically do not undergo prostate biopsy.
Suspicious areas scoring 3, 4 or 5 on either bpMRI or mpMRI will undergo targeted and systematic biopsy using the information from the mpMRI to influence biopsy conduct. Suspicious areas will be labelled by their MRI score, with their location according to sector diagrams.
The proportion of patients with clinically significant prostate cancer will be ascertained and compared between bpMRI and mpMRI.
Treatment eligibility decisions without the DCE information will be made and once the clinicians are unblinded to the DCE sequence the impact that this information makes on the treatment decision will be evaluated.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||500 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Within-person controlled, paired cohort, diagnostic evaluation study. Participants undergo two index tests and a reference test.|
|Masking:||Single (Care Provider)|
|Masking Description:||Radiologist assessing MRI for suspicion of prostate cancer is blinded to the contrast sequence when reporting the biparametric MRI. After this report, they are unblinded to the contrast sequence and report the multiparametric MRI. All biopsies conducted as a result of MRI findings will be labelled as bpMRI and mpMRI, and diagnostic accuracy will be assessed against histology findings.|
|Official Title:||A Study Comparing Bi-parametric MRI to Multi-parametric MRI in the Diagnosis of Clinically Significant Prostate Cancer|
|Actual Study Start Date :||April 5, 2022|
|Estimated Primary Completion Date :||December 2023|
|Estimated Study Completion Date :||March 2024|
Active Comparator: mpMRI
Diagnostic Test: Multiparametric MRI +/- prostate biopsy
MRI with T2-weighted, diffusion weighted and dynamic contrast enhanced sequences followed by prostate biopsy if indicated on MRI and clinical findings
Diagnostic Test: Biparametric MRI +/- prostate biopsy
MRI with T2-weighted and diffusion weighted sequences followed by prostate biopsy if indicated on MRI and clinical findings
- Proportion of men with clinically significant cancer [ Time Frame: When biopsy results available, at an expected average of 30 days post-biopsy ]
- Proportion of men with clinically insignificant cancer (Gleason grade 3+3 / Gleason grade group 1) [ Time Frame: When biopsy results available, at an expected average of 30 days post-biopsy ]
- Agreement between bpMRI and mpMRI for score of suspicion [ Time Frame: When MRI results available, at an expected average of 30 days post-MRI ]Score of suspicion on MRI (1-5) - lowest score = 1 = highly unlikely to be significant cancer. Highest score = 5 = highly likely to be significant cancer. For MRI to be non-suspicious it needs to be scored 1 or 2 on both Likert and PIRADSv2.1 systems. For MRI to be suspicious it can to be scored 3, 4 or 5 on either Likert or PIRADSv2.1 systems.
- Agreement between bpMRI and mpMRI for radiological staging decision [ Time Frame: When MRI results available, at an expected average of 30 days post-MRI ]
- Agreement between bpMRI and mpMRI for treatment eligibility [ Time Frame: When treatment options discussed in multidisciplinary meeting, at an expected average of 30 days post intervention ]At the coordinating centre, in a multi-disciplinary team meeting, treatment eligibility decisions without the DCE information will be made and once the clinicians are unblinded to the DCE sequence the impact that this information makes on the treatment decision will be evaluated.
- Test performance characteristics for bpMRI & mpMRI when using the Likert scoring system in comparison to the PIRADS scoring system [ Time Frame: When biopsy results available, at an expected average of 30 days post-MRI ]
- Proportion of men with cancer missed by bpMRI and mpMRI-targeted biopsies and detected by systematic biopsy [ Time Frame: When biopsy results available, at an expected average of 30 days post-biopsy ]
- Cost-effectiveness of BpMRI compared to mpMRI (cost per diagnosis of prostate cancer) [ Time Frame: At an expected average of 30 days post-intervention ]A within-trial analysis will be conducted to calculate the total cost for bpMRI and mpMRI and mean cost per patient if a strategy of bpMRI or mpMRI were adopted. The cost per diagnosis of clinically significant cancer will be calculated for bpMRI and mpMRI. An incremental cost effectiveness ratio may be calculated by deriving the additional cost per case of clinically significant cancer diagnosed. The cost of avoiding each additional case of clinically insignificant cancer diagnosed may also be calculated. Consideration will be given to extending this analysis using economic modelling to allow a lifetime perspective to be taken and the estimation of quality adjusted life years (QALYs). Costs of procedures will be estimated by multiplying standard unit costs by key resource using data captured within the trial. If possible, standard unit costs (e.g. NHS Reference costs) will be supplemented by unit cost data (and uncertainty around these costs) from the participating trial sites.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||Male|
|Accepts Healthy Volunteers:||No|
- Men at least 18 years of age referred with clinical suspicion of prostate cancer
- Serum PSA ≤ 20ng/ml
- Fit to undergo all procedures listed in protocol
- Able to provide written informed consent
- Prior prostate biopsy
- Prior treatment for prostate cancer
- Prior prostate MRI on a previous encounter
- Contraindication to MRI
- Contraindication to prostate biopsy
- Unfit to undergo any procedures listed in protocol
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04571840
|Contact: Veeru Kasivisvanathan, MBBS PhD||0207 679 firstname.lastname@example.org|
|Contact: Pramit Khetrapal, MBBS PhD||0207 679 email@example.com|
|Study Chair:||Veeru Kasivisvanathan, MBBS PhD||University College, London|
|Principal Investigator:||Caroline Moore, MD FRCS||University College, London|
|Principal Investigator:||Mark Emberton, MD FRCS||University College, London|
|Principal Investigator:||Clare Allen, FRCR||University College London Hospital|
|Principal Investigator:||Shonit Punwani, PhD FRCR||University College, London|
|Principal Investigator:||Francesco Giganti, MD||University College, London|
|Responsible Party:||University College, London|
|Other Study ID Numbers:||
|First Posted:||October 1, 2020 Key Record Dates|
|Last Update Posted:||May 18, 2022|
|Last Verified:||May 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
|Plan Description:||Anonymised data will be available at request for bona fide researchers with important research questions subject to approval by the study steering committee.|
Statistical Analysis Plan (SAP)
|Time Frame:||Data will become available 1 year after publication of the main study results.|
|Access Criteria:||A study steering committee will review all requests for access to the data and will make decisions on whether or not to grant access to bona fide researchers based on the importance of the research question being asked, ensuring analysis is non overlapping with existing analyses and planned analyses.|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||Yes|
Genital Neoplasms, Male
Neoplasms by Site